GOOD buying opportunity,
While the USA is in later-stage clinical trials, EMD is gaining experience and RWD on actually delivering the clinical service and wrap-around support. I can see the USA doing a deal here once they have approval, as arguably we will have the most experience of any company globally (no one in the USA will have the skills as its only able to be done at the research level), and leverage that into our mdma analogs.
Australia is deff a number of years ahead of any counterpart. and just like cannabis we will quickly grow our dataset from 0 to >10,000.
Pax has some nice revenue as well.
GOOD buying opportunity, While the USA is in later-stage...
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 89097 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 45000 | 1 |
View Market Depth
| Last trade - 10.23am 03/07/2024 (20 minute delay) ? |
| EMD (ASX) Chart |
Day chart unavailable